Previous 10 | Next 10 |
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Halozyme Therapeutics, inc (NASDAQ: HALO) Q3 2021 Earnings Call Nov 2, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcrip...
Halozyme Therapeutics, Inc. (HALO) Q3 2021 Earnings Conference Call November 03, 2021, 04:30 PM ET Company Participants Al Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and CEO Elaine Sun - CFO Conference Call Participants Charles Duncan ...
A 145% increase in royalties in Q3 2021, primarily from sales of Darzalex (daratumumab), helped lead Halozyme Therapeutics (NASDAQ:HALO) to an earnings beat. Royalty revenue in the quarter was $58.6M, up from $23.9M in the prior-year period. Net product sales surged ~177% to ~25M. Operating e...
Halozyme Therapeutics (NASDAQ:HALO): Non-GAAP EPS of $0.55 beats by $0.07; GAAP EPS of $1.48 beats by $1.06. Revenue of $115.83M beats by $9.99M. Press Release Guidance Revenues of $430 million to $445 million, increased from prior guidance of $425 million to $445 million, representing year-o...
Halozyme Reports Third Quarter 2021 Results - Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 - - Third Quarter Revenue of $115.8 million with GAAP Diluted Earnings per Share of $1.48 and Non-GAAP Diluted Earn...
Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , Oct. 19, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on...
Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed. Small Pharma Analyst shares a lon...
Low risk biotech with steadily increasing revenue and earnings from ENHANZE drug delivery. Revenue and earnings are expected to peak at end of the decade with a long tail into the mid-2030s. Sizeable earnings provide ample cash for acquisitions or partnerships that will likely kee...
Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference PR Newswire SAN DIEGO , Sept. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun , senior vice president and chief financial ...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...